Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma

Abstract Our aim was to evaluate the prognostic value of initial total metabolic tumour volume (TMTV) in a population of patients with advanced-stage Hodgkin’s lymphoma (HL). We retrospectively included 179 patients with stage IIb-III-IV Hodgkin’s disease who received BEACOPP or ABVD as the first-li...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pierre Pinochet, Edgar Texte, Aspasia Stamatoullas-Bastard, Pierre Vera, Sorina-Dana Mihailescu, Stéphanie Becker
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/320f75b681c74ec0bc9a3bdf937d9037
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:320f75b681c74ec0bc9a3bdf937d9037
record_format	dspace
spelling	oai:doaj.org-article:320f75b681c74ec0bc9a3bdf937d90372021-12-05T12:13:35ZPrognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma10.1038/s41598-021-02734-w2045-2322https://doaj.org/article/320f75b681c74ec0bc9a3bdf937d90372021-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02734-whttps://doaj.org/toc/2045-2322Abstract Our aim was to evaluate the prognostic value of initial total metabolic tumour volume (TMTV) in a population of patients with advanced-stage Hodgkin’s lymphoma (HL). We retrospectively included 179 patients with stage IIb-III-IV Hodgkin’s disease who received BEACOPP or ABVD as the first-line treatment. The initial TMTV was determined using a semi-automatic method for each patient. We analysed its prognostic value in terms of 5-year progression-free survival (PFS), overall survival, and positron emission tomography (PET) response after two courses of chemotherapy. Considering all the treatments and using a threshold of 217 cm3, TMTV was predictive of 5-year PFS and PET response after two courses of chemotherapy. In multivariable analysis involving TMTV, IPI score, and the first treatment received, TMTV remained a baseline prognostic factor for 5-year PFS. In the subgroup of patients treated with BEACOPP with a threshold of 331 cm3, TMTV was predictive of PET response, but not 5-year PFS (p = 0.087). The combined analysis of TMTV and PET response enabled the individualisation of a subgroup of patients (low TMTV and complete response on PET) with a very low risk of recurrence. Baseline TMTV appears to be a useful independent prognostic factor for predicting relapse in advanced-stage HL in ABVD subgroup, with a tendency of survival curves separation in BEACOPP subgroup.Pierre PinochetEdgar TexteAspasia Stamatoullas-BastardPierre VeraSorina-Dana MihailescuStéphanie BeckerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pierre Pinochet Edgar Texte Aspasia Stamatoullas-Bastard Pierre Vera Sorina-Dana Mihailescu Stéphanie Becker Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
description	Abstract Our aim was to evaluate the prognostic value of initial total metabolic tumour volume (TMTV) in a population of patients with advanced-stage Hodgkin’s lymphoma (HL). We retrospectively included 179 patients with stage IIb-III-IV Hodgkin’s disease who received BEACOPP or ABVD as the first-line treatment. The initial TMTV was determined using a semi-automatic method for each patient. We analysed its prognostic value in terms of 5-year progression-free survival (PFS), overall survival, and positron emission tomography (PET) response after two courses of chemotherapy. Considering all the treatments and using a threshold of 217 cm3, TMTV was predictive of 5-year PFS and PET response after two courses of chemotherapy. In multivariable analysis involving TMTV, IPI score, and the first treatment received, TMTV remained a baseline prognostic factor for 5-year PFS. In the subgroup of patients treated with BEACOPP with a threshold of 331 cm3, TMTV was predictive of PET response, but not 5-year PFS (p = 0.087). The combined analysis of TMTV and PET response enabled the individualisation of a subgroup of patients (low TMTV and complete response on PET) with a very low risk of recurrence. Baseline TMTV appears to be a useful independent prognostic factor for predicting relapse in advanced-stage HL in ABVD subgroup, with a tendency of survival curves separation in BEACOPP subgroup.
format	article
author	Pierre Pinochet Edgar Texte Aspasia Stamatoullas-Bastard Pierre Vera Sorina-Dana Mihailescu Stéphanie Becker
author_facet	Pierre Pinochet Edgar Texte Aspasia Stamatoullas-Bastard Pierre Vera Sorina-Dana Mihailescu Stéphanie Becker
author_sort	Pierre Pinochet
title	Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
title_short	Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
title_full	Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
title_fullStr	Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
title_full_unstemmed	Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
title_sort	prognostic value of baseline metabolic tumour volume in advanced-stage hodgkin’s lymphoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/320f75b681c74ec0bc9a3bdf937d9037
work_keys_str_mv	AT pierrepinochet prognosticvalueofbaselinemetabolictumourvolumeinadvancedstagehodgkinslymphoma AT edgartexte prognosticvalueofbaselinemetabolictumourvolumeinadvancedstagehodgkinslymphoma AT aspasiastamatoullasbastard prognosticvalueofbaselinemetabolictumourvolumeinadvancedstagehodgkinslymphoma AT pierrevera prognosticvalueofbaselinemetabolictumourvolumeinadvancedstagehodgkinslymphoma AT sorinadanamihailescu prognosticvalueofbaselinemetabolictumourvolumeinadvancedstagehodgkinslymphoma AT stephaniebecker prognosticvalueofbaselinemetabolictumourvolumeinadvancedstagehodgkinslymphoma
_version_	1718372124892069888

Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma

Ejemplares similares